- Home
- RCUS vs PCN Comparison
RCUS vs PCN Comparison
Compare RCUS & PCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- PCN
- Stock Information
- Founded
- RCUS 2015
- PCN 2001
- Country
- RCUS United States
- PCN United States
- Employees
- RCUS N/A
- PCN N/A
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- PCN Investment Managers
- Sector
- RCUS Health Care
- PCN Finance
- Exchange
- RCUS Nasdaq
- PCN Nasdaq
- Market Cap
- RCUS 906.4M
- PCN 810.6M
- IPO Year
- RCUS 2018
- PCN N/A
- Fundamental
- Price
- RCUS $8.92
- PCN $12.74
- Analyst Decision
- RCUS Buy
- PCN
- Analyst Count
- RCUS 11
- PCN 0
- Target Price
- RCUS $25.33
- PCN N/A
- AVG Volume (30 Days)
- RCUS 1.2M
- PCN 218.7K
- Earning Date
- RCUS 05-06-2025
- PCN 01-01-0001
- Dividend Yield
- RCUS N/A
- PCN 9.73%
- EPS Growth
- RCUS N/A
- PCN N/A
- EPS
- RCUS N/A
- PCN N/A
- Revenue
- RCUS $141,000,000.00
- PCN N/A
- Revenue This Year
- RCUS N/A
- PCN N/A
- Revenue Next Year
- RCUS $29.83
- PCN N/A
- P/E Ratio
- RCUS N/A
- PCN N/A
- Revenue Growth
- RCUS N/A
- PCN N/A
- 52 Week Low
- RCUS $6.50
- PCN $10.70
- 52 Week High
- RCUS $18.98
- PCN $14.48
- Technical
- Relative Strength Index (RSI)
- RCUS 53.03
- PCN 48.79
- Support Level
- RCUS $8.42
- PCN $12.65
- Resistance Level
- RCUS $9.61
- PCN $12.77
- Average True Range (ATR)
- RCUS 0.49
- PCN 0.10
- MACD
- RCUS 0.06
- PCN 0.00
- Stochastic Oscillator
- RCUS 48.89
- PCN 61.54
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About PCN Pimco Corporate & Income Strategy Fund
PIMCO Corporate & Income Strategy Fund is a closed-end management investment company. Its objective is to seek high current income with capital appreciation as a secondary objective. It invests in corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, short-term instruments, and others.